Company Overview: Actinium Pharmaceuticals Inc

Industry News

21 Mar

Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B

NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has received positive Scientific Advice from the Committee for Medicinal Products for Human...

Read more

17 Mar

Actinium Pharmaceuticals to Sponsor 4th Annual Summit on Hematologic Malignancies

NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is a sponsor of Oncology Meeting Innovations’ 4thAnnual Summit on Hematologic Malignancies, which is...

Read more

7 Mar

Actinium Pharmaceuticals to Present at 29th Annual ROTH Conference

NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Sandesh Seth, Actinium’s Executive Chairman, will be presenting at 29th Annual ROTH Conference being held March...

Read more

28 Feb

Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform

NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company received a notice of allowance from the United States Patent and Trademark Office...

Read more

21 Feb

Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy

NEW YORK, Feb. 21, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Steven Price has been appointed to the newly created position of Vice President, Clinical and Commercial...

Read more

14 Feb

Actinium Pharmaceuticals to Attend the BMT Tandem Meetings, the Combined Annual Meetings of Two Leading Transplant Organizations

NEW YORK, Feb. 14, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that representatives from the Company’s executive and clinical development teams will be attending the BMT Tandem Meetings,...

Read more

13 Feb

Actinium Pharmaceuticals’ Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma

NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Sandesh Seth, Actinium’s Executive Chairman, will be presenting at the BIO CEO & Investor Conference being...

Read more

9 Feb

Actinium Pharmaceuticals to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Sandesh Seth, Actinium’s Executive Chairman, will be presenting at the BIO CEO & Investor Conference being...

Read more

7 Feb

Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma

NEW YORK, Feb. 07, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that a Phase 1 clinical trial studying Actimab-M in multiple myeloma has been initiated. Actimab-M is comprised...

Read more

24 Jan

Actinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative Neoplasms

NEW YORK, Jan. 24, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that recently appointed Chief Medical Officer, Dr. Mark Berger, has been selected to present at the 3rd Annual...

Read more

Page 1 of 912345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address